HEALTH
-
Government-Paid Health Insurance Wins Decisive U.S. Majority 2026
Government-paid health insurance secures overwhelming two-thirds majority backing from American voters ahead of high-stakes congressional midterm elections.
Read More » -
Ebola Evacuation Directive Denies US Doctors Return Home 2026
Ebola evacuation directive issued by the White House bars infected American physicians in the Democratic Republic of Congo from returning…
Read More » -
Denecimig FDA Approval: Novo Nordisk Hemophilia A Filing 2026
Denecimig FDA approval application progresses as Novo Nordisk seeks landmark hemophilia A indication for patients with and without inhibitors.
Read More » -
Medicare Advantage Plans Face Network Cuts by Major US Health Insurers 2026
Medicare Advantage plans are tightening provider networks as UnitedHealthcare and CVS Health Aetna respond to escalating medical care costs.
Read More » -
Nuclear weapons tests in Marshall Islands Left Severe Human Cost, UN Finds 2026
Nuclear weapons tests conducted by the US across the Marshall Islands inflicted severe, lasting harm demanding just compensation, a landmark…
Read More » -
Cuba Water Crisis Deepens Across Havana Tenements Amid Blackouts 2026
Cuba water crisis deepens as residents in Old Havana scramble during blackouts to collect basic supplies after crumbling systems leave…
Read More » -
Wegovy Pill Sustains Weight Loss After Switch From Injections 2026
Wegovy pill clinical trial results demonstrate continued weight loss after switching from GLP-1 injections, reinforcing Novo Nordisk's market lead.
Read More » -
US :ADARx Pharmaceuticals Raises $446M in Upsized US Biotech IPO
ADARx Pharmaceuticals secures $446.3 million in an upsized US initial public offering, signaling revitalized Wall Street confidence in clinical RNA…
Read More » -
Obamacare health insurance Costs Force Hard Choices for Workers 2026
Obamacare health insurance price surges leave self-employed Americans choosing between vital preventive medical care and business survival in rural communities.
Read More » -
Remigromig Meets Primary Goal in Merck Clinical Eye Disease Trial 2026
Remigromig demonstrates non-inferiority against ranibizumab in Merck's mid-to-late-stage clinical trial evaluating diabetic macular edema treatments.
Read More »